

FDT.04890	<b>Unique Specimen Labeling</b>	Phase II
	 <b>The written accessioning procedure requires unique labeling of each specimen by the laboratory.</b>	
FDT.04950	<b>Restricted Access</b>	Phase II
	 <b>Access to specimens, aliquots and any extracts thereof is restricted to authorized laboratory personnel.</b>	
FDT.05000	<b>Accessioning Procedure</b>	Phase II
	 <b>The laboratory follows an accessioning procedure that defines criteria for determining the acceptability of specimens for analysis and the course of action when unacceptable specimens are identified.</b>	
	<i>NOTE: Evaluation criteria such as chain-of-custody failures, missing information, specimen leakage, etc. must be defined in the accessioning procedure, along with the required actions that laboratory personnel must take in reporting these problems to the client.</i>	
FDT.05020	<b>Specimen Acceptability</b>	Phase II
	 <b>The laboratory follows a written procedure for determining the quality of specimens received for analysis and course of action when unacceptable specimens are detected (eg, color, odor, volume, quantity, foreign material, etc.).</b>	
	<i>NOTE: This procedure must require the visual inspection of samples and assessment of the sample volume/quantity for acceptability for analysis, at minimum.</i>	
	<b>Evidence of Compliance:</b>	
	<ul style="list-style-type: none"><li>✓ Records of specimen evaluation</li></ul>	
	<b>REFERENCES</b>	
	1) Clinical and Laboratory Standards Institute (CLSI). <i>Toxicology and Drug Testing in the Medical Laboratory</i> . 3rd ed. CLSI guideline C52. Clinical and Laboratory Standards Institute, Wayne, PA; 2017.	
FDT.05045	<b>Specimen Validity - Urine</b>	Phase II
	 <b>All urine specimens are tested for validity.</b>	
	<i>NOTE: At a minimum, this requires a test for creatinine but may also include measurements of specific gravity, pH, etc. The laboratory is required to discuss the issue of excessively dilute specimens and potential adulteration with its clients.</i>	
	<b>Evidence of Compliance:</b>	
	<ul style="list-style-type: none"><li>✓ Records of specimen validity testing</li></ul>	
	<b>REFERENCES</b>	
	1) Clinical and Laboratory Standards Institute (CLSI). <i>Toxicology and Drug Testing in the Medical Laboratory</i> . 3rd ed. CLSI guideline C52. Clinical and Laboratory Standards Institute, Wayne, PA; 2017.	
FDT.05055	<b>External Contamination - Hair and Nails</b>	Phase II
	 <b>The laboratory follows validated procedures to control for potential external contamination of hair and nail specimens.</b>	
	<i>NOTE: This may include wash procedures and/or metabolite identification.</i>	
FDT.05095	<b>Secured Specimen Storage</b>	Phase II